Acceptance and commitment therapy for moral injury (ACT-MI) and present-centered therapy for moral injury (PCT-MI): Results from a randomized controlled pilot trial with war zone deployed veterans.

Psychotherapy (Chic)Jul 27, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Lauren M Borges, Jacob K Farnsworth, Robyn D Walser et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled pilot trial evaluated Acceptance and Commitment Therapy for Moral Injury (ACT-MI) and Present-Centered Therapy for Moral Injury (PCT-MI) among 74 war zone-deployed veterans. Both therapies were found acceptable, with ACT-MI showing a significant improvement in psychosocial functioning (M = -17.45) compared to PCT-MI (M = -5.89).

Key findings

  • ACT-MI had a Client Satisfaction Questionnaire score of M = 29.52, indicating high acceptability.
  • PCT-MI had a Client Satisfaction Questionnaire score of M = 26.41, also reflecting good acceptability.
  • ACT-MI showed a greater reduction in psychosocial dysfunction (M = -17.45) compared to PCT-MI (M = -5.89).

Why it matters

Understanding the effectiveness and acceptability of these therapies is crucial for addressing moral injury in veterans, which can significantly impact their mental health and overall well-being.

Source

PubMed · PMID 42507361Free full text on PubMed Central

Published in Psychotherapy (Chic). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.